Vertex Pharmaceuticals (VRTX) Cash from Investing Activities (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Cash from Investing Activities of -$431.9 million for Q1 2026, down 674.01% year-over-year from $75.2 million in Q1 2025, and down 49.91% quarter-over-quarter from -$288.1 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Cash from Investing Activities (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$431.9 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 674.01% year-over-year to -$431.9 million; the TTM figure through Mar 2026 stood at -$1.3 billion (up 21.78% YoY), while the FY2025 annual figure was -$945.4 million, up 74.92% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$431.9 million, down from -$288.1 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $175.6 million in Q4 2022, with the low at -$2.1 billion in Q1 2024.
- The 5-year median for Cash from Investing Activities is -$348.0 million (2024), against an average of -$506.5 million.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities soared 231.04% in 2022, then tumbled 3495.29% in 2023.
- Vertex Pharmaceuticals' Cash from Investing Activities stood at $175.6 million in 2022, then tumbled by 604.84% to -$886.5 million in 2023, then advanced by 7.29% to -$821.9 million in 2024, then soared by 64.95% to -$288.1 million in 2025, then plunged by 49.91% to -$431.9 million in 2026.
- Business Quant data shows VRTX's Cash from Investing Activities at -$431.9 million in Q1 2026, -$288.1 million in Q4 2025, and -$117.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 281.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.80 Mn |
| Jun 30, 2026 | -45.80 Mn |
| Mar 31, 2026 | -431.90 Mn |
| Mar 31, 2026 | -431.90 Mn |
| Dec 31, 2025 | -288.10 Mn |
| Dec 31, 2025 | -288.10 Mn |
| Sep 30, 2025 | -117.00 Mn |
| Sep 30, 2025 | -117.00 Mn |
| Jun 30, 2025 | -484.50 Mn |
| Jun 30, 2025 | -484.50 Mn |
| Mar 31, 2025 | -55.80 Mn |
| Mar 31, 2025 | -55.80 Mn |
| Dec 31, 2024 | -821.90 Mn |
| Dec 31, 2024 | -821.90 Mn |
| Sep 30, 2024 | -348.00 Mn |
| Sep 30, 2024 | -348.00 Mn |
| Jun 30, 2024 | -463.70 Mn |
| Jun 30, 2024 | -463.70 Mn |
| Mar 31, 2024 | -2.14 Bn |
| Mar 31, 2024 | -2.14 Bn |